Drug Shortage Report for SODIUM CHLORIDE INJECTION, USP

Last updated on 2022-10-05 History
Report ID 158798
Drug Identification Number 02139510
Brand name SODIUM CHLORIDE INJECTION, USP
Common or Proper name Sodium Chloride Injection, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) SODIUM CHLORIDE
Strength(s) 234MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 100mL
ATC code B05XA
ATC description I.V. SOLUTION ADDITIVES
Reason for shortage Other (Please describe in comments)
Anticipated start date
Actual start date 2021-10-01
Estimated end date 2022-11-01
Actual end date 2022-10-04
Shortage status Resolved
Updated date 2022-10-05
Company comments We will be encountering a supply interruption on our Sodium Chloride Injection, USP 4mEq/mL Maxivial® 100 mL effective September 1, 2022 until November 1, 2022. Effective September 1, 2022 allocations for our 200 mL will be increased to cover 100% of 200mL demand plus 100% of 100 mL demand on a mL:mL basis. Please see communication for further details.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v13 2022-10-05 English Compare
v12 2022-10-03 French Compare
v11 2022-10-03 English Compare
v10 2022-09-01 French Compare
v9 2022-09-01 English Compare
v8 2022-08-21 French Compare
v7 2022-08-21 English Compare
v6 2022-07-29 French Compare
v5 2022-07-29 English Compare
v4 2022-06-27 French Compare
v3 2022-06-27 English Compare
v2 2022-04-13 French Compare
v1 2022-04-13 English Compare

Showing 1 to 13 of 13